Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1978 1
1979 3
1980 1
1981 2
1982 6
1983 3
1984 5
1986 5
1987 2
1988 3
1989 3
1990 4
1991 5
1992 3
1993 8
1994 4
1995 2
1996 1
1997 6
1998 5
1999 1
2000 5
2001 1
2002 6
2003 4
2004 3
2005 7
2006 9
2007 5
2008 5
2009 9
2010 4
2011 5
2012 6
2013 3
2014 3
2015 5
2016 8
2017 10
2018 11
2019 3
2020 5
2021 6
2022 7
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Results by year

Filters applied: . Clear all
Page 1
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Backes J, Anzalone D, Hilleman D, Catini J. Backes J, et al. Lipids Health Dis. 2016 Jul 22;15(1):118. doi: 10.1186/s12944-016-0286-4. Lipids Health Dis. 2016. PMID: 27444154 Free PMC article. Review.
DHA-containing formulations may also increase low-density lipoprotein cholesterol. However, this is not accompanied by increased non-high-density lipoprotein cholesterol, which is thought to provide a better indication of cardiovascular risk in this patient populati …
DHA-containing formulations may also increase low-density lipoprotein cholesterol. However, this is not accompanied by increased non- …
Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives.
Vinci P, Di Girolamo FG, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Altamura N, Pirulli A, Zaccari M, Biasinutto C, Roni C, Fiotti N, Schincariol P, Mangogna A, Biolo G. Vinci P, et al. Int J Environ Res Public Health. 2023 Sep 6;20(18):6721. doi: 10.3390/ijerph20186721. Int J Environ Res Public Health. 2023. PMID: 37754581 Free PMC article. Review.
It can increase the risk of developing cardiovascular disease even when LDL cholesterol (LDL-C) levels are within the recommended range, which is referred to as residual cardiovascular risk. ...Indeed, high concentrations of Lp(a) have been related to …
It can increase the risk of developing cardiovascular disease even when LDL cholesterol (LDL-C) levels are within the r …
Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia.
Bove M, Fogacci F, Cicero AFG. Bove M, et al. Expert Opin Drug Metab Toxicol. 2017 Oct;13(10):1099-1104. doi: 10.1080/17425255.2017.1381085. Epub 2017 Sep 26. Expert Opin Drug Metab Toxicol. 2017. PMID: 28922021 Review.
Cholesterol lowering treatment is mainly based on statins eventually associated to adjunctive drugs of different class such as ezetimibe. ...The available evidence support the clinical efficacy of this drug combination, both in term of LDL-cholesterol reducti …
Cholesterol lowering treatment is mainly based on statins eventually associated to adjunctive drugs of different class such as ezetim …
Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen.
Zhang J, Rocha NA, McCullough PA. Zhang J, et al. Rev Cardiovasc Med. 2018 Mar 30;19(1):13-19. doi: 10.31083/j.rcm.2018.01.890. Rev Cardiovasc Med. 2018. PMID: 31032598 Free article. Review.
Diabetic dyslipidemia in type 2 diabetes (T2DM) is characterized by elevated levels of triglycerides (TG), decreased levels of high density lipoprotein-cholesterol (HDL-C), elevated levels of low density lipoprotein-cholesterol (LDLC), and the predominance of …
Diabetic dyslipidemia in type 2 diabetes (T2DM) is characterized by elevated levels of triglycerides (TG), decreased levels of high d …
PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance.
Voutyritsa E, Damaskos C, Farmaki P, Kyriakos G, Diamantis E, Quiles-SÁnchez LV, Garmpi A, Garmpis N, Patsouras A, Stelianidi A, Savvanis S. Voutyritsa E, et al. In Vivo. 2021 Jan-Feb;35(1):61-68. doi: 10.21873/invivo.12232. In Vivo. 2021. PMID: 33402450 Free PMC article. Review.
Thus, numerous patients are not treated with suitable statin-based therapy or take only very low doses. As a result, the desired decrease in low-density lipoprotein cholesterol (LDL-C) is not achieved, resulting in patients at a high risk for cardiovas …
Thus, numerous patients are not treated with suitable statin-based therapy or take only very low doses. As a result, the desired d …
Treatment of hyperlipidemia.
Gotto AM Jr. Gotto AM Jr. Am J Cardiol. 1986 May 30;57(14):11G-16G. doi: 10.1016/0002-9149(86)90660-0. Am J Cardiol. 1986. PMID: 3521247 Review.
The National Heart, Lung, and Blood Institute's Coronary Primary Prevention Trial showed that diet and drug therapy lower cholesterol by 9% and low density lipoprotein (LDL) cholesterol by 12.5%, on average, in at-risk patients compared with control su …
The National Heart, Lung, and Blood Institute's Coronary Primary Prevention Trial showed that diet and drug therapy lower choleste …
Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies.
Patel RS, Scopelliti EM, Savelloni J. Patel RS, et al. Pharmacotherapy. 2015 Dec;35(12):1189-203. doi: 10.1002/phar.1672. Pharmacotherapy. 2015. PMID: 26684558 Review.
Familial hypercholesterolemia (FH) is a genetic disorder characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) concentrations that result from mutations of the LDL receptor, apolipoprotein B (apo B-100), and proprotein con …
Familial hypercholesterolemia (FH) is a genetic disorder characterized by significantly elevated low-density lipoprotein cholesterol …
The role of fibrate treatment in dyslipidemia: an overview.
Katsiki N, Nikolic D, Montalto G, Banach M, Mikhailidis DP, Rizzo M. Katsiki N, et al. Curr Pharm Des. 2013;19(17):3124-31. doi: 10.2174/1381612811319170020. Curr Pharm Des. 2013. PMID: 23317397 Review.
Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) concentrations, represents a major …
Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), …
PCSK9 inhibition in the management of familial hypercholesterolemia.
Ogura M. Ogura M. J Cardiol. 2018 Jan;71(1):1-7. doi: 10.1016/j.jjcc.2017.07.002. Epub 2017 Aug 5. J Cardiol. 2018. PMID: 28784313 Free article. Review.
Familial hypercholesterolemia (FH) is a frequent hereditary metabolic disease characterized by high serum low-density lipoprotein (LDL) cholesterol concentration and premature atherosclerotic cardiovascular disease (ASCVD). ...Additionally, the strong LDL …
Familial hypercholesterolemia (FH) is a frequent hereditary metabolic disease characterized by high serum low-density lipoprotein (LDL …
APOE Genotype Disclosure and Lifestyle Advice in a Randomized Intervention Study with Finnish Participants.
Leskinen HM, Tringham M, Karjalainen H, Iso-Touru TK, Hietaranta-Luoma HL, Marnila PJ, Pihlava JM, Hurme T, Kankaanpää SJ, Puolijoki H, Åkerman K, Tanner L, Sandell M, Vähäkangas K, Hopia A, Tahvonen R, Rokka LS. Leskinen HM, et al. J Nutr. 2021 Jan 4;151(1):85-97. doi: 10.1093/jn/nxaa316. J Nutr. 2021. PMID: 33188400 Free article.
The lifestyle guidance increased vegetable consumption from 3.5 to 3.6 portions/d, improved the dietary fat quality score by 5.3%, increased the plasma n-3 (omega-3) FA proportion by 7.3%, and decreased the consumption of high-fat/high-sugar foods from 7.3 to 6.5 portions/ …
The lifestyle guidance increased vegetable consumption from 3.5 to 3.6 portions/d, improved the dietary fat quality score by 5.3%, increased …
196 results